ANCA-associated vasculitis (AAV) is an autoimmune disorder characterized by inflammation of small vessels, posing substantial diagnostic and therapeutic challenges despite advancements in medical research. The complexity of its immunopathogenesis, combined with the variety of clinical manifestations and the difficulty in predicting treatment responses and outcomes, accentuates the need for a deeper understanding of the disease. Notable among recent studies is the focus on the immunological roles of ANCAs, neutrophil activation, and cytokine networks, yielding promising therapeutic targets yet to be fully translated into clinical practice.

This Research Topic aims to illuminate the intricate nature of AAV and streamline the translation of scientific research into therapeutic innovation. The overarching goal is to publish comprehensive analyses and syntheses of current data to assist clinicians, students, and researchers in optimizing care for patients affected by AAV. Specifically, the research seeks to provide an updated synthesis of immunopathological findings, evaluate novel biomarkers for predicting disease activity, and review current and emerging treatment modalities that promise personalized medicine approaches.

To gather further insights within this field, we welcome articles addressing, but not limited to, the following themes:

• Detailed mechanisms of immune response and potential therapeutic targets in AAV

• Genetic and environmental factors influencing ANCA production and disease manifestation

• The role and validation of novel biomarkers in disease monitoring and prognosis

• Clinical features of AAV with a focus on systemic impacts and comorbid conditions

• New insights into the prognosis, disease monitoring, and risk stratification of patients

• Evaluative studies on current and novel therapeutic strategies, including biologic agents

Together, these contributions will foster a richer, more precise understanding of AAV, improving both clinical outcomes and patients' quality of life.

RZ has served on the advisory boards for Amgen, Travere Therapeutics, and Otsuka pharmaceuticals, and has received speaking fees from Amgen and Novartis.
AS receives Honoraria from Vifor, Chiesi, and Sarepta therapeutics

Are you interested in contributing a manuscript to this Research Topic?

Comprehensive Insights into ANCA Vasculitis: From Immunopathology to Treatment Strategies

Topic Coordinator